CSIMarket Company Name, Ticker, Industry, else..
 
Paxmedica Inc   (NONE: PXMD)
Other Ticker:  
 
 
Price: $0.0310 $-0.01 -22.500%
Day's High: $0.031 Week Perf: -46.92 %
Day's Low: $ 0.03 30 Day Perf: -55.71 %
Volume (M): 1 52 Wk High: $ 1.19
Volume (M$): $ 0 52 Wk Avg: $0.30
Open: $0.03 52 Wk Low: $0.03



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 8
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Paxmedica Inc
Paxmedica Inc is a medical technology company that specializes in the development and manufacturing of innovative healthcare products. The company focuses on creating advanced solutions that enhance patient care and improve clinical outcomes. Paxmedica Inc's products are designed to meet the needs of healthcare professionals and patients, with a particular emphasis on safety, efficacy, and user-friendliness. The company aims to contribute to the evolution of the healthcare industry by integrating cutting-edge technology and research into their product development process.


   Company Address: 101 Arch Street, 8th Floor Boston 2110 MA
   Company Phone Number: 216-1459   Stock Exchange / Ticker: NONE PXMD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD   -1.84%    
ALKS        3.95% 
BMRN   -8.15%    
REGN   -4.93%    
SUPN        0.45% 
VRTX        2.09% 
• View Complete Report
   



Announcement

PaxMedica Appeals Nasdaq Delisting and Prepares for FDA Meeting on PAX-101

Published Wed, May 15 2024 12:30 PM UTC

New York-based biopharmaceutical company, PaxMedica, Inc. (OTC:PXMD), is currently facing a delisting threat by Nasdaq. In response, PaxMedica has taken swift action by filing an appeal with the Nasdaq Office of Appeals and Review. The company also announced its preparations for an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding its innovative dru...
Paxmedica Inc

Paxmedica Inc's First Quarter of 2024 Earnings Season Reveals Operating Deficit of $-4.036675 Million2.

The stock market is abuzz with news of PaxMedica Inc.'s recent developments that have caught investors' attention. The company's unexpected moderations in business operations during the January to March 31, 2024 reporting cycle have left stockholders pleasantly surprised.
One particular aspect that investors are closely monitoring is the operating deficit of PaxMedica Inc., which stood at $-3.690163 million during the same period. However, compared to the previous year, the company's management has taken significant strides forward in efficiently handling day-to-day operations, overshadowing the deficit. This is especially evident in their commitment to research, as it has become one of the main takeaways from this news.
Management Announcement

PaxMedica Steps Up to Combat Sleeping Sickness Crisis in Malawi with Emergency Supply of IV Suramin

Published Tue, Apr 23 2024 12:30 PM UTC

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
PaxMedica Inc. (Nasdaq: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, has announced its swift response to an urgent request from the Ministry of Health (MOH) of Malawi in east Africa. The MOH seeks emergency...
Management Announcement

PaxMedica Revolutionizes Autism Spectrum Disorder Treatments with Groundbreaking Innovations

Published Wed, Mar 13 2024 12:20 PM UTC

PaxMedica Unveils Innovations in Autism Spectrum Disorder Treatments in Latest Company Presentation
TARRYTOWN, New York, March 13, 2024 - PaxMedica, Inc. (NASDAQ: PXMD), a leading biopharmaceutical company specializing in neurological disorder treatments, announced today the release of its latest company presentation. This comprehensive overview highlights PaxMedica s st...
Paxmedica Inc

Paxmedica Inc. Discloses Disappointing Fourth Quarter Results for 2023

The stock market can often be a rollercoaster ride, with ups and downs that can leave investors feeling uncertain and apprehensive. However, it's important to stay positive and look for opportunities even in challenging times.
One such company that has faced its fair share of obstacles is Paxmedica Inc, a major player in the field of pharmaceutical preparations. For the fiscal period from October to December 2023, the company experienced a top-line stagnation, disappointing stockholders who had hoped for some growth.
Despite this setback, investors are closely monitoring Paxmedica Inc's operating shortfall, which stood at $-4.386136 million during the same period. This metric provides valuable insights into the company's financial health and is crucial for understanding its overall performance.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com